Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) on Monday, plunged -3.34% from the previous trading day, before settling in for the closing price of $54.80. Within the past 52 weeks, RYTM’s price has moved between $35.17 and $68.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 189.02%. The company achieved an average annual earnings per share of 41.66%. With a float of $56.93 million, this company’s outstanding shares have now reached $62.39 million.
Let’s determine the extent of company efficiency that accounts for 283 employees. In terms of profitability, gross margin is 89.44%, operating margin of -204.04%, and the pretax margin is -199.98%.
Rhythm Pharmaceuticals Inc (RYTM) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Rhythm Pharmaceuticals Inc is 9.96%, while institutional ownership is 95.02%. The most recent insider transaction that took place on Mar 21 ’25, was worth 18,655. In this transaction Corporate Controller & CAO of this company sold 344 shares at a rate of $54.23, taking the stock ownership to the 2,889 shares. Before that another transaction happened on Mar 14 ’25, when Company’s EVP, Head of International sold 75,000 for $51.48, making the entire transaction worth $3,861,272. This insider now owns 40,370 shares in total.
Rhythm Pharmaceuticals Inc (RYTM) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.63 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 41.66% per share during the next fiscal year.
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Trading Performance Indicators
Rhythm Pharmaceuticals Inc (RYTM) is currently performing well based on its current performance indicators. A quick ratio of 3.08 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -1.33 in one year’s time.
Technical Analysis of Rhythm Pharmaceuticals Inc (RYTM)
Looking closely at Rhythm Pharmaceuticals Inc (NASDAQ: RYTM), its last 5-days average volume was 0.51 million, which is a drop from its year-to-date volume of 0.52 million. As of the previous 9 days, the stock’s Stochastic %D was 54.33%. Additionally, its Average True Range was 2.30.
During the past 100 days, Rhythm Pharmaceuticals Inc’s (RYTM) raw stochastic average was set at 24.66%, which indicates a significant decrease from 49.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.62% in the past 14 days, which was lower than the 47.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $55.18, while its 200-day Moving Average is $52.16. However, in the short run, Rhythm Pharmaceuticals Inc’s stock first resistance to watch stands at $53.74. Second resistance stands at $54.51. The third major resistance level sits at $55.62. If the price goes on to break the first support level at $51.87, it is likely to go to the next support level at $50.76. Should the price break the second support level, the third support level stands at $49.99.
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) Key Stats
Market capitalization of the company is 3.35 billion based on 63,224K outstanding shares. Right now, sales total 130,130 K and income totals -260,600 K. The company made 41,830 K in profit during its latest quarter, and -43,330 K in sales during its previous quarter.
